• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[程序性死亡受体1/程序性死亡受体配体1在三阴性乳腺癌中的表达及其意义]

[Expression of PD-1/PD-L1 in triple-negative breast carcinoma and its significance].

作者信息

Zhang W, Xu G X, Li J J, Liu X, Chen Y J, Zhang F

机构信息

Department of Pathology, Wannan Medical College Yijishan Hospital, Wuhu 241001, China.

出版信息

Zhonghua Bing Li Xue Za Zhi. 2017 Jan 8;46(1):20-24. doi: 10.3760/cma.j.issn.0529-5807.2017.01.005.

DOI:10.3760/cma.j.issn.0529-5807.2017.01.005
PMID:28072971
Abstract

To investigate the correlation between the expression of PD-1, PD-L1 and clinicopathologic parameters in triple negative breast carcinoma (TNBC). Samples from 151 patients with TNBC and 65 cases of other breast carcinomas (non-TNBC) were examined for PD-L1 and PD-1 expression by immunohistochemical staining on tissue microarray. The expression of PD-L1 and PD-1 in the tumor cells and interstitial lymphocytes in TNBC was significantly (<0.05)higher than that in non-TNBC.In TNBC, the expression rates of PD-L1 in the cancer nests and stroma were 16.6%(25/151) and 25.2%(38/151)respectively.The former was positively correlated with tumor histological grade and lymph node metastasis (<0.05), and the latter only with tumor histological grade (<0.05). The expression rate of PD-1 was 27.2% (41/151), and correlated with PD-L1 expression in stromal tumor-infiltrating lymphocytes (<0.05). The expression of PD-L1 in TNBC is significantly correlated with high-grade histology, lymph node metastasis and PD-L1 expression in stromal tumor-infiltrating lymphocytes.

摘要

探讨三阴性乳腺癌(TNBC)中PD-1、PD-L1表达与临床病理参数之间的相关性。通过组织芯片免疫组化染色检测151例TNBC患者及65例其他乳腺癌(非TNBC)患者样本中PD-L1和PD-1的表达情况。TNBC肿瘤细胞和间质淋巴细胞中PD-L1和PD-1的表达显著(<0.05)高于非TNBC。在TNBC中,癌巢和间质中PD-L1的表达率分别为16.6%(25/151)和25.2%(38/151)。前者与肿瘤组织学分级和淋巴结转移呈正相关(<0.05),后者仅与肿瘤组织学分级相关(<0.05)。PD-1的表达率为27.2%(41/151),与间质肿瘤浸润淋巴细胞中PD-L1的表达相关(<0.05)。TNBC中PD-L1的表达与高级别组织学、淋巴结转移及间质肿瘤浸润淋巴细胞中PD-L1的表达显著相关。

相似文献

1
[Expression of PD-1/PD-L1 in triple-negative breast carcinoma and its significance].[程序性死亡受体1/程序性死亡受体配体1在三阴性乳腺癌中的表达及其意义]
Zhonghua Bing Li Xue Za Zhi. 2017 Jan 8;46(1):20-24. doi: 10.3760/cma.j.issn.0529-5807.2017.01.005.
2
[Correlation analysis of PD-L1 expression and prognosis in triple-negative breast cancers].三阴性乳腺癌中PD-L1表达与预后的相关性分析
Zhonghua Bing Li Xue Za Zhi. 2017 Dec 8;46(12):822-826. doi: 10.3760/cma.j.issn.0529-5807.2017.12.002.
3
Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.三阴性乳腺癌原发肿瘤与配对淋巴结转移灶中 PD-L1 表达的异质性。
BMC Cancer. 2018 Jan 2;18(1):4. doi: 10.1186/s12885-017-3916-y.
4
The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).免疫检查点抑制剂的治疗候选物由三阴性乳腺癌(TNBC)中肿瘤浸润淋巴细胞(TILs)和程序性死亡配体 1(PD-L1)表达的状态所阐明。
Breast Cancer. 2018 Jan;25(1):34-42. doi: 10.1007/s12282-017-0781-0. Epub 2017 May 9.
5
Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer.基质程序性死亡受体配体1表达与三阴性乳腺癌更好的无病生存期相关。
Am J Clin Pathol. 2016 Oct;146(4):496-502. doi: 10.1093/ajcp/aqw134.
6
High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients.高 PD-L1 表达与肿瘤浸润淋巴细胞密切相关,并导致中国三阴性乳腺癌患者的良好临床结局。
Int J Biol Sci. 2017 Sep 5;13(9):1172-1179. doi: 10.7150/ijbs.20868. eCollection 2017.
7
The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.Foxp3+/CD25+ 调节性 T 细胞和 PD-L1 表达在三阴性乳腺癌中的预测和预后价值。
Ann Diagn Pathol. 2019 Jun;40:143-151. doi: 10.1016/j.anndiagpath.2019.04.004. Epub 2019 Apr 10.
8
Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.Syntenin1/MDA-9 (SDCBP) 通过上调 PD-L1 在三阴性乳腺癌中诱导免疫逃逸。
Breast Cancer Res Treat. 2018 Sep;171(2):345-357. doi: 10.1007/s10549-018-4833-8. Epub 2018 May 29.
9
PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.PD-L1表达及肿瘤浸润性PD-1+淋巴细胞与HER2+乳腺癌患者的预后相关。
Breast Cancer Res Treat. 2017 Feb;162(1):19-30. doi: 10.1007/s10549-016-4095-2. Epub 2017 Jan 5.
10
The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.在炎性乳腺癌中,同时存在 CD20+B 细胞和 PD-L1+肿瘤浸润淋巴细胞与患者预后改善相关。
Breast Cancer Res Treat. 2018 Sep;171(2):273-282. doi: 10.1007/s10549-018-4834-7. Epub 2018 Jun 1.

引用本文的文献

1
Pan-Cancer Molecular Characterization of mA Regulators and Immunogenomic Perspective on the Tumor Microenvironment.mA调控因子的泛癌分子特征及肿瘤微环境的免疫基因组学视角
Front Oncol. 2021 Jan 28;10:618374. doi: 10.3389/fonc.2020.618374. eCollection 2020.
2
Protective effect of hsa-miR-570-3p targeting CD274 on triple negative breast cancer by blocking PI3K/AKT/mTOR signaling pathway.hsa-miR-570-3p 通过靶向 CD274 阻断 PI3K/AKT/mTOR 信号通路对三阴性乳腺癌的保护作用。
Kaohsiung J Med Sci. 2020 Aug;36(8):581-591. doi: 10.1002/kjm2.12212. Epub 2020 Apr 20.